ישראל: הטיפול נגד סרטן הלבלב הגרורתי

הערכה

The FDA has approved Draxonarciv, a drug targeting the RAS protein, for metastatic pancreatic cancer. It shows unprecedented survival improvements, but the monthly cost of about 90,000 NIS creates a serious access barrier. Professor Ido Wolf warns that patients without private insurance may be unable to afford it. The gap between medical breakthrough and financial reality is now the central tension.